Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
K. Waellnitz, I. Duijkers, C. Klipping, T. Rautenberg, B. Rohde & C. Zurth. (2016) A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women. Journal of Obstetrics and Gynaecology 36:1, pages 106-113.
Read now
Read now
Robin Kroll, Larry Seidman, Nancy Ricciotti, Brandon Howard & Herman Weiss. (2015) A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. The European Journal of Contraception & Reproductive Health Care 20:4, pages 249-258.
Read now
Read now
A. Patrick Schneider, Christine M. Zainer, Christopher Kevin Kubat, Nancy K. Mullen & Amberly K. Windisch. (2014) The breast cancer epidemic: 10 facts. The Linacre Quarterly 81:3, pages 244-277.
Read now
Read now
Abdelhamid M Attia, Magdy M Ibrahim & Ahmed M Abou-Setta. (2013) Role of the levonorgestrel intrauterine system in effective contraception. Patient Preference and Adherence 7, pages 777-785.
Read now
Read now
Carolina Scala, Umberto Leone Roberti Maggiore, Valentino Remorgida, Pier Luigi Venturini & Simone Ferrero. (2013) Drug safety evaluation of desogestrel
. Expert Opinion on Drug Safety 12:3, pages 433-444.
Read now
Read now
Ana Cristina Rebelo, Nayara Tamburús, Mariana Salviati, Vanessa Celante, Anielle Takahashi, Marcos Felipe de Sá, Aparecida Catai & Ester Silva. (2011) Influence of third-generation oral contraceptives on the complexity analysis and symbolic dynamics of heart rate variability. The European Journal of Contraception & Reproductive Health Care 16:4, pages 289-297.
Read now
Read now
C. Di Carlo, G. A. Tommaselli, V. Gargano, F. Savoia, G. Bifulco & C. Nappi. (2010) Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 13:5, pages 442-446.
Read now
Read now
Ann-Britt Wiréhn, Anniqa Foldemo, Ann Josefsson & Malou Lindberg. (2010) Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. The European Journal of Contraception & Reproductive Health Care 15:1, pages 41-47.
Read now
Read now
Giuseppe Benagiano, Sabina Carrara & Valentina Filippi. (2009) Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Preference and Adherence 3, pages 131-143.
Read now
Read now
Giuseppe Benagiano, Carlo Bastianelli & Manuela Farris. (2008) Selective progesterone receptor modulators 1: use during pregnancy. Expert Opinion on Pharmacotherapy 9:14, pages 2459-2472.
Read now
Read now
M. Caprio, M.-C. Zennaro, B. Fève, C. Mammi, A. Fabbri & G. Rosano. (2008) Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor. Climacteric 11:3, pages 258-264.
Read now
Read now
Inka Wiegratz & Herbert Kuhl. (2006) Metabolic and clinical effects of progestogens. The European Journal of Contraception & Reproductive Health Care 11:3, pages 153-161.
Read now
Read now
Articles from other publishers (34)
Ashley M. Strzelecki, Cassandra D. Gipson, Emma Childs & Jessica Weafer. (2023) Preliminary evidence of increased alcohol use associated with ethinyl estradiol levels in women using oral contraceptives. Drug and Alcohol Dependence Reports 9, pages 100194.
Crossref
Crossref
Aastha SahuHarish SharmaRajesh Kumar NemaGyanesh Kumar Sahu. (2023) Innovation and Challenges in Male Contraception. Global Journal of Medical, Pharmaceutical, and Biomedical Update 18, pages 17.
Crossref
Crossref
Manuel García-Sáenz, Raúl Ibarra-Salce, Francisco Javier Pozos-Varela, Tania Sofia Mena-Ureta, Susana Flores-Villagómez, Mario Santana-Mata, Ramón G. De Los Santos-Aguilar, Daniel Uribe-Cortés & Aldo Ferreira-Hermosillo. (2023) Understanding Progestins: From Basics to Clinical Applicability. Journal of Clinical Medicine 12:10, pages 3388.
Crossref
Crossref
Erin E. Maher, Ashley M. Strzelecki, Jessica J. Weafer & Cassandra D. Gipson. (2023) The importance of translationally evaluating steroid hormone contributions to substance use. Frontiers in Neuroendocrinology 69, pages 101059.
Crossref
Crossref
Konstantinos AnastassakisKonstantinos Anastassakis. 2022. Androgenetic Alopecia From A to Z. Androgenetic Alopecia From A to Z
187
192
.
Dan Martin, Simon B. Cooper, Jonathan C.Y. Tang, William D. Fraser, Craig Sale & Kirsty J. Elliott-Sale. (2021) Bone metabolic marker concentrations across the menstrual cycle and phases of combined oral contraceptive use. Bone 145, pages 115864.
Crossref
Crossref
Alexandra Ycaza Herrera, Sophia Faude, Shawn E. Nielsen, Mallory Locke & Mara Mather. (2019) Effects of hormonal contraceptive phase and progestin generation on stress-induced cortisol and progesterone release. Neurobiology of Stress 10, pages 100151.
Crossref
Crossref
Arunoday Bhan & Subhrangsu S. Mandal. 2017. Gene Regulation, Epigenetics and Hormone Signaling. Gene Regulation, Epigenetics and Hormone Signaling
289
328
.
Renate Louw-du Toit, Karl-Heinz Storbeck, Meghan Cartwright, Angelique Cabral & Donita Africander. (2017) Progestins used in endocrine therapy and the implications for the biosynthesis and metabolism of endogenous steroid hormones. Molecular and Cellular Endocrinology 441, pages 31-45.
Crossref
Crossref
Daniel MARTIN & Kirsty ELLIOTT-SALE. (2016) A perspective on current research investigating the effects of hormonal contraceptives on determinants of female athlete performance. Revista Brasileira de Educa??o F?sica e Esporte 30:4, pages 1087-1096.
Crossref
Crossref
Cristina Scavone, Angela Colomba Bonagura, Sonia Fiorentino, Daniela Cimmaruta, Rosina Cenami, Marco Torella, Tiziano Fossati & Francesco Rossi. (2016) Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data. Drugs in R&D 16:2, pages 129-140.
Crossref
Crossref
Robin Kroll, Ronald Ackerman, Robert Feldman, Brandon Howard, Herman Weiss, Jennifer Hsieh & Nancy Ricciotti. (2016) Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol. Contraception 93:3, pages 249-256.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
459
493
.
Christian Zurth, Barbara Schuett, Manuela Casjens, Matthias Ludwig & Katrin Waellnitz. (2015) Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study. Clinical Pharmacology in Drug Development 4:4, pages 245-255.
Crossref
Crossref
M. Merz, R. Kroll, R. Lynen & K. Bangerter. (2015) Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. Contraception 91:2, pages 113-120.
Crossref
Crossref
D. Gruber, A. Sk?iv?nek, M. Serrani, V. Lanius & M. Merz. (2015) A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study. Contraception 91:2, pages 105-112.
Crossref
Crossref
Inka Wiegratz, Susana Bassol, Edith Weisberg, Uwe Mellinger & Martin Merz. (2014) Effect of a Low-Dose Contraceptive Patch on Efficacy, Bleeding Pattern, and Safety: A 1-Year, Multicenter, Open-Label, Uncontrolled Study. Reproductive Sciences 21:12, pages 1518-1525.
Crossref
Crossref
Carolyn L. Westhoff, Isabel Reinecke, Keith Bangerter & Martin Merz. (2014) Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Contraception 90:3, pages 272-279.
Crossref
Crossref
Elisabeth F. Beaber, Diana S.M. Buist, William E. Barlow, Kathleen E. Malone, Susan D. Reed & Christopher I. Li. (2014) Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Research 74:15, pages 4078-4089.
Crossref
Crossref
Elisabeth F. Beaber, Kathleen E. Malone, Mei-Tzu Chen Tang, William E. Barlow, Peggy L. Porter, Janet R. Daling & Christopher I. Li. (2014) Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women. Cancer Epidemiology, Biomarkers & Prevention 23:5, pages 755-764.
Crossref
Crossref
Martin Merz & Julia Grunert. (2014) Effects of an Ethinyl Estradiol/Gestodene Transdermal Contraceptive Patch on the Endometrium: A Single-Center, Uncontrolled Study. Women's Health 10:1, pages 37-43.
Crossref
Crossref
Nobutaka Tasaka, Koji Matsumoto, Toyomi Satoh, Takeo Minaguchi, Mamiko Onuki, Hiroyuki Ochi, Yumiko O Tanaka, Akiko Sakata, Masayuki Noguchi & Hiroyuki Yoshikawa. (2013) Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report. SpringerPlus 2:1.
Crossref
Crossref
Wolfgang Junge, Doris Heger-Mahn, Dietmar Trummer & Martin Merz. (2013) Investigation of the Hemostatic Effect of a Transdermal Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene Compared with a Monophasic Oral Contraceptive Containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel: An Open-Label, Randomized, Crossover Study. Drugs in R&D 13:3, pages 223-233.
Crossref
Crossref
José A. Guerra, Francisco López-Muñoz & Cecilio Álamo. (2013) Progestins in Combined Contraceptives. Journal of Experimental & Clinical Medicine 5:2, pages 51-55.
Crossref
Crossref
M.A. Blanco-Molina, M. Lozano, A. Cano, I. Cristobal, L.P. Pallardo & I. Lete. (2012) Progestin-only contraception and venous thromboembolism. Thrombosis Research 129:5, pages e257-e262.
Crossref
Crossref
Jan Endrikat, Christoph Gerlinger, Stephanie Richard, Peter Rosenbaum & Bernd Düsterberg. (2011) Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception 84:6, pages 549-557.
Crossref
Crossref
Hidetaka Okada, Rika Okamoto, Tomoko Tsuzuki, Shoko Tsuji, Katsuhiko Yasuda & Hideharu Kanzaki. (2011) Progestins inhibit estradiol-induced vascular endothelial growth factor and stromal cell–derived factor 1 in human endometrial stromal cells. Fertility and Sterility 96:3, pages 786-791.
Crossref
Crossref
David F. ArcherIgnacio Lete Lasa. (2011) Tailoring Combination Oral Contraceptives to the Individual Woman. Journal of Women's Health 20:6, pages 879-891.
Crossref
Crossref
Markus Herrmann & Markus J. Seibel. (2010) The effects of hormonal contraceptives on bone turnover markers and bone health. Clinical Endocrinology 72:5, pages 571-583.
Crossref
Crossref
Christopher I Li & Elisabeth F Beaber. 2010. Breast Cancer Epidemiology. Breast Cancer Epidemiology
89
117
.
Jan Endrikat, Susanne Parke, Dietmar Trummer, Werner Schmidt, Ingrid Duijkers & Christine Klipping. (2008) Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 78:3, pages 218-225.
Crossref
Crossref
Galina Lurie, Pamela Thompson, Katharine E. McDuffie, Michael E. Carney, Keith Y. Terada & Marc T. Goodman. (2007) Association of Estrogen and Progestin Potency of Oral Contraceptives With Ovarian Carcinoma Risk. Obstetrics & Gynecology 109:3, pages 597-607.
Crossref
Crossref
Hongjian Zhang, Donghui Cui, Bonnie Wang, Yong-Hae Han, Praveen Balimane, Zheng Yang, Michael Sinz & A David Rodrigues. (2007) Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol. Clinical Pharmacokinetics 46:2, pages 133-157.
Crossref
Crossref
Ian Thorneycroft, Pavel Klein & James Simon. (2006) The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy & Behavior 9:1, pages 31-39.
Crossref
Crossref